Conversely, mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus, reduce the incidence of cancer by suppressing p70 S6K, interleukin-10, and cyclin; downregulating VEGF; and inducing apoptosis (4). Here, MTOR is linked to cancer.